期刊文献+

Flanibizumab Plus Combined Surgery for Treatment o Neovascular Glaucoma with Vitreous Hemorrhage 被引量:13

Flanibizumab Plus Combined Surgery for Treatment o Neovascular Glaucoma with Vitreous Hemorrhage
原文传递
导出
摘要 Background:Neovascular glaucoma (NVG) is a refractory glaucoma.The management of NVG is very difficult,and it is more difficult when combined with vitreous hemorrhage.The aim of this study was to investigate the effects of ranibizumab plus combined surgery for NVG with vitreous hemorrhage.Methods:A total of 26 eyes of 26 NVG patients with vitreous hemorrhage were recruited in this study.The patients aged from 36 to 63 years with a mean age of 51.97 ± 7.60 years.The mean intraocular pressure (IOP) was 46.38 ± 5.75 mmHg (1 mmHg =0.133 kPa) while being treated with the maximum medical therapy.The mean best-corrected visual acuities converted to logarithm of the minimum angle of resolution (logMAR BCVA) was 2.62 ± 0.43.All the patients underwent intravitreal injection of 0.5 mg (0.05 ml) ranibizumab combined with pars plana vitrectomy (PPV),pars plana lensectomy (PPL) with a preserved anterior capsule,panretinal photocoagulation (PRP),and trabeculectomy (intravitreal ranibizumab [IVR] + PPV + PPL + PRP + trabeculectomy).The IOP and logMAR BCVA were the main outcome measures in this study.Results:The follow-up period was 12 months.The mean postoperative IOPs were 26.38 ± 3.75 mmHg,21.36 ± 3.32 mmHg,1 8.57 ± 3.21 mmHg,and 16.68 ± 2.96 mmHg,respectively at 7 days,1 month,3 months,and 12 months after PPV + PPL + PRP + trabeculectomy.At the last follow-up,the mean IOP was significantly lower than the preoperative one (t =6.612,P =0.001).At 7 days,1 month,3 months,and 12 months after PPV + PPL + PRP + trabeculectomy,the mean logMAR BCVA were 1.30 ± 0.36,1.29 ± 0.37,1.29 ± 0.39,and 1.26 ± 0.29,respectively.At the last follow-up,the mean logMAR BCVA was significantly improved,and the difference was statistically significant compared with preoperative one (t =6.133,P =0.002).The logMAR BCVA improved in 22 eyes (84.62%),and remained stable in 4 eyes (15.38%).The neovascularization in the iris and the angle regressed significantly in all patients 7 days after ranibizumab injection.No serious complications occurred during 12 months of the study.Conclusions:IVR + PPV + PPL + PRP + trabeculectomy can control IOP well and improve BCVA without severe complication for NVG patients with vitreous hemorrhage. Background:Neovascular glaucoma (NVG) is a refractory glaucoma.The management of NVG is very difficult,and it is more difficult when combined with vitreous hemorrhage.The aim of this study was to investigate the effects of ranibizumab plus combined surgery for NVG with vitreous hemorrhage.Methods:A total of 26 eyes of 26 NVG patients with vitreous hemorrhage were recruited in this study.The patients aged from 36 to 63 years with a mean age of 51.97 ± 7.60 years.The mean intraocular pressure (IOP) was 46.38 ± 5.75 mmHg (1 mmHg =0.133 kPa) while being treated with the maximum medical therapy.The mean best-corrected visual acuities converted to logarithm of the minimum angle of resolution (logMAR BCVA) was 2.62 ± 0.43.All the patients underwent intravitreal injection of 0.5 mg (0.05 ml) ranibizumab combined with pars plana vitrectomy (PPV),pars plana lensectomy (PPL) with a preserved anterior capsule,panretinal photocoagulation (PRP),and trabeculectomy (intravitreal ranibizumab [IVR] + PPV + PPL + PRP + trabeculectomy).The IOP and logMAR BCVA were the main outcome measures in this study.Results:The follow-up period was 12 months.The mean postoperative IOPs were 26.38 ± 3.75 mmHg,21.36 ± 3.32 mmHg,1 8.57 ± 3.21 mmHg,and 16.68 ± 2.96 mmHg,respectively at 7 days,1 month,3 months,and 12 months after PPV + PPL + PRP + trabeculectomy.At the last follow-up,the mean IOP was significantly lower than the preoperative one (t =6.612,P =0.001).At 7 days,1 month,3 months,and 12 months after PPV + PPL + PRP + trabeculectomy,the mean logMAR BCVA were 1.30 ± 0.36,1.29 ± 0.37,1.29 ± 0.39,and 1.26 ± 0.29,respectively.At the last follow-up,the mean logMAR BCVA was significantly improved,and the difference was statistically significant compared with preoperative one (t =6.133,P =0.002).The logMAR BCVA improved in 22 eyes (84.62%),and remained stable in 4 eyes (15.38%).The neovascularization in the iris and the angle regressed significantly in all patients 7 days after ranibizumab injection.No serious complications occurred during 12 months of the study.Conclusions:IVR + PPV + PPL + PRP + trabeculectomy can control IOP well and improve BCVA without severe complication for NVG patients with vitreous hemorrhage.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2015年第15期2078-2083,共6页 中华医学杂志(英文版)
关键词 Neovascular Glaucoma Panretinal Photocoagulation Pars Plana Vitrectomy RANIBIZUMAB TRABECULECTOMY Neovascular Glaucoma Panretinal Photocoagulation Pars Plana Vitrectomy Ranibizumab Trabeculectomy
  • 相关文献

参考文献3

二级参考文献46

  • 1Mahmut Kaya,Zeynep Ozbek,Aylin Yaman,Ismet Durak.Long-term success of ahmed glaucoma valve in refractory glaucoma[J].International Journal of Ophthalmology(English edition),2012,5(1):108-112. 被引量:15
  • 2Levine R,Brucker AJ,Robinson F.Long-term follow-up of idiopathic central serous chorioretinopathy by fluorescein angiography.Ophthalmology 1989; 96:854-859.
  • 3Loo RH,Scott IU,Flynn HW Jr,Gass JD,Murray TG,Lewis ML,et al.Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy.Retina 2002; 22:19-24.
  • 4Hussain D,Gass JD.Idiopathic central serous chorioretinopathy.Indian J Ophthalmol 1998; 46:131-137.
  • 5Taban M,Boyer DS,Thomas EL,Taban M.Chronic central serous chorioretinopathy:photodynamic therapy.Am J Ophthalmol 2004; 137:1073-1080.
  • 6Pikkel J,Beiran I,Ophir A,Miller B.Acetazolamide for central serous retinopathy.Ophthalmology 2002; 109:1723-1725.
  • 7Bujarborua D,Chatterjee S,Choudhury A,Bori G,Sarma AK.Fluorescein angiographic features of asymptomatic eyes in central serous chorioretinopathy.Retina 2005; 25:422-429.
  • 8Burumcek E,Mudun A,Karacorlu S,Arslan MO.Laser photocoagulation for persistent central serous retinopathy:results of long-term follow-up.Ophthalmology 1997; 104:616-622.
  • 9Battaglia Parodi M,Da Pozzo S,Ravalico G.Photodynamic therapy in chronic central serous chorioretinopathy.Retina 2003; 23:235-237.
  • 10Colucciello M.Choroidal neovascularization complicating photodynamic therapy for central serous retinopathy.Retina 2006; 26:239-242.

共引文献51

同被引文献68

引证文献13

二级引证文献79

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部